Prem Premsrirut is an expert in the development and use of RNAi transgenic mice for fast and flexible validation and toxicity assessment of candidate genes targets in vivo. She was an inventor of technological advancements that lead to the development of a high-throughput platform for rapid and efficient generation of conditional RNAi transgenic mice and pioneered a novel approach for the generation of “speedy” chimeric GEMMs based on rederivation of mouse embryonic stem cells (ESCs) from existing mouse strains with a predisposition to cancer. Dr. Premsrirut was an MD/PhD fellow at SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory. She received her Ph.D. in genetics and cancer biology following her training in the laboratory of Dr. Scott Lowe. Her work focused on the development of transgenic mouse models to study the effects of tumor maintenance on lung cancer using RNA interference. She received a B.A. in Molecular Cell Biology and Biochemistry from UC Berkeley. She previously worked in the lab of Dr. Ravi Iyengar at Mount Sinai School of Medicine, where she studied the downstream effects heterotrimeric G-proteins coupled to muscarinic, dopamine and adrenergic receptors in order to gain an understanding of the signal transduction pathways that play a role in opioid addiction and neuronal development.

Prem Premsrirut is a President and CEO of Mirimus, a company established in 2010 with the goal of creating a scalable and cost effective pipeline for model generation by harnessing the power of RNAi and CRISPR technologies to develop animal models which are crucial for preclinical evaluation of new therapeutics.